(MedPage Today) — The FDA has approved the topical phosphodiesterase 4 (PDE4) inhibitor difamilast (Adquey) as a new option for mild/moderate atopic dermatitis (AD).
The approval allows for use in adults and pediatric patients at least 2 years…
Source:
www.medpagetoday.com
Medical Disclaimer:
This content is shared for informational and educational purposes only.
It does not constitute medical, legal, or policy advice.
Healthcare decisions should always be made in consultation with qualified professionals.
